SOPHiA GENETICS Q3 Results Could Not Be Verified Ahead of November 3 Conference
Key Facts
SOPHiA GENETICS’ third-quarter 2026 results could not be verified from a reliable public source as of the date this report was prepared, so the revenue figures or updated annual guidance in the initial account cannot be confirmed. The company’s investor relations website listed a conference to discuss third-quarter results on Tuesday, November 3, from 8:00 to 9:00 a.m. Eastern Time. Until then, the latest figures available in the materials provided are the second-quarter results published in August. The company reported revenue of $23.3 million at the time, up 27% year over year. That figure provides context on the company’s earlier performance, but does not establish its revenue or growth in the third quarter.
In the second quarter, the company said its U.S. revenue rose 64% year over year, while business volume there increased 60%. The figures highlight the U.S. market among the growth drivers reported at the time, with revenue growing faster than business volume. But they relate to the second quarter and do not show the U.S. contribution to third-quarter results. They also do not, on their own, establish that subsequent growth came from AI-powered precision medicine, a characterization not verified in the evidence on the new results. An assessment of third-quarter performance remains contingent on the release of official figures and details.
On margins, the reported gross margin was 64.6% in the second quarter of 2026, versus 67.0% in the same period a year earlier. Adjusted gross margin was 72.1%, compared with 74.4% in the second quarter of 2025. The comparison points to year-over-year declines in both measures during that period, despite revenue growth. These figures do not describe the third quarter and cannot be used to infer the direction of margins after June. They also do not establish the third-quarter adjusted EBITDA loss, as the figure in the initial account could not be verified from a reliable public source.
In its second-quarter earnings announcement, the company raised its 2026 revenue guidance to a range of $94 million to $96 million, from $92 million to $94 million. It said at the time that the new range implied year-over-year growth of 22% to 24%. The claim that the company now expects to reach the top of the range therefore cannot be confirmed based on the available evidence; the verified range establishes that guidance was updated in the second quarter, not that a new update was announced in the third quarter. An assessment of any annual update depends on an earnings statement that could not be verified in these materials. It also cannot be established that exchange-rate fluctuations will weigh on fourth-quarter revenue, as that warning was not confirmed by a reliable public source.
The company processed a record 115,000 analyses on the SOPHiA DDM platform in the second quarter, up 22% year over year. It had 542 core genomics customers as of June 30, 2026, compared with 490 a year earlier, and said it signed 24 new customers in that segment during the quarter. Cash and cash equivalents totaled $107.7 million at the end of the second quarter. These indicators offer a picture of business volume, its commercial base and liquidity at the end of June, but do not update its position at the end of September. The company’s conference scheduled for November 3 is the listed date for discussing third-quarter results, according to its investor relations page.